| Identification | Back Directory | [Name]
Lincomycin | [CAS]
154-21-2 | [Synonyms]
U-10149
Myvicin
U-10149A
Albiotic
jiemycin
Lincocine
NSC-70731
Lincolcina
Cillimycin
LINCOMYCIN
LYNCOMYCIN
lincomycina
Lincomycine
Lincomyocin
trans-alpha
Lincolnensin
LINCOMYCIN STANDARD
Lincomycin hydrochoride
Lincomycin(baseand/orunspecifiedsalt)
Lincomycin HCL Bp98 USP24 EPIII CP2000
hro-d-galacto-octopyranoside(alpha-form)
Linocin, Lincolnensin, U 10149, JieMycin
Lincomycin (base and/or unspecified salts)
trans-alpha--pyrrolidinecarboxamido)-1-thio
Methyl-D-erythro-a-D-galacto-octopyranoside
trans-alpha-opyl-2-pyrrolidinyl)carbonyl)amino)-1-thio
d-erythro-d-galacto-octopyranoside,methyl6,8-dideoxy-6-(1-methyl-4-propyl-l-2
d-erythro-alpha-d-galacto-octopyranoside,methyl6,8-dideoxy-6-(((1-methyl-4-pr
d-erythro-d-galacto-octopyranoside,methyl-6,8-dideoxy-6-(1-methyl-4-propyl-l-2
methyl6,8-dideoxy-6-(1-methyl-4-propyl-2-pyrrolidinecarboxamido)-1-thio-d-eryt
Methyl 6,8-dideoxy-6-([(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino)-1-thiooctopyranoside
Methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-D-erythro-alpha-D-galacto-octopyranoside
(2S-trans)-Methyl 6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-D-threo-a-D-galacto-octopyranoside
Methyl 6,8-dideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-D-erythro-alpha-D-gluco-octopyranoside
D-erythro-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-
D-erythro-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-a-(8CI)
D-erythro-a-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, (2S-trans)-
D-erythro-a-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-(9CI)
D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, (2S-trans)-
(2S-trans)-Methyl 6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-D-threo-α-D-galacto-octopyranoside Hydrochloride
(2S-trans)-Methyl 6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-D-threo-a-D-galacto-octopyranoside Hydrochloride
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide | [EINECS(EC#)]
205-824-6 | [Molecular Formula]
C18H34N2O6S | [MDL Number]
MFCD00135816 | [MOL File]
154-21-2.mol | [Molecular Weight]
406.54 |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Usage]
An antibiotic produced by Streptomyces lincolnensis. Antibacterial | [Usage]
Lincomycin is a polar, water soluble, broad spectrum antibiotic first isolated from Streptomyces licolnensis by researchers at Upjohn in 1962. Lincomycin was the first of a unique structural class, the lincosamides, containing a rare amino acid, 4-propyl-N-methylproline, coupled to an equally rare aminomethylthio-octopyranoside sugar. Lincomycin and semi-synthetic analogues are often incorrectly considered to be aminoglycosides but share little or no structural similarity. Lincomycin is a broad spectrum antibiotic with activity against anaerobic bacteria and protozoans. Lincomycin acts by binding to the 23S ribosomal subunit, blocking protein synthesis. Lincomycin has been extensively studied with over 7,000 literature citations. | [Uses]
An antibiotic produced by Streptomyces lincolnensis. Antibacterial | [Uses]
Lincomycin is a polar, water soluble, broad spectrum antibiotic first isolated from Streptomyces licolnensis by researchers at Upjohn in 1962. Lincomycin was the first of a unique structural class, the lincosamides, containing a rare amino acid, 4-propyl-N-methylproline, coupled to an equally rare aminomethylthio-octopyranoside sugar. Lincomycin and semi-synthetic analogues are often incorrectly considered to be aminoglycosides but share little or no structural similarity. Lincomycin is a broad spectrum antibiotic with activity against anaerobic bacteria and protozoans. Lincomycin acts by binding to the 23S ribosomal subunit, blocking protein synthesis. Lincomycin has been extensively studied with over 7,000 literature citations. | [Definition]
ChEBI: A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis. | [Description]
Lincomycin is an antibiotic active against grampositive
bacteria. Occupational exposure occurs in
poultry and pig breeders.
| [Originator]
Lincocin,Upjohn,UK,1964 | [Manufacturing Process]
As described in US Patent 3,086,912, the process comprises cultivating
Streptomyces lincolnensis var. lincolnensis in an aqueous nutrient medium
containing a source of assimilable carbohydrate and assimilable nitrogen
under aerobic conditions until substantial activity is imparted to the medium
by production of lincolnensin and isolating the lincolnensin so produced. | [Brand name]
Lincocin (Pharmacia & Upjohn). | [Therapeutic Function]
Antibacterial | [Antimicrobial activity]
Lincomycin has an antibacterial effect with respect to Gram-positive microorganisms
(staphylococci, streptococci, pneumococci, diphtheria bacillus, and clostridia). It is used
for serious bacterial infections: sepsis, osteomyelitis, septic endocarditis, pneumonia, pulmonary abscess, infected wounds, and purulent meningitis. Lincomycin is a reserve drug
for infections caused by strains of staphylococci and other Gram-positive microorganisms
that are resistant to penicillin and other antibiotics. Synonyms of this drug are lincocin,
mycivin, albiotic, and others. | [General Description]
Lincomycin was found in the culture broth of Streptomyces lincolnensis var. lincolnensis by the Upjohn Co. in 1962. It shows antibacterial activity similar to that of the macrolide antibiotics and also shows excellent activity against anaerobic bacteria. Lincomycin is used clinically in combination with other classes of antibiotics for postoperative, gynecological, urinary tract, ear and nose, and other infections. | [Clinical Use]
Lincomycin is a natural product isolated from fermentations of Streptomyces lincolnensisvar. lincolnensis. It
is active against Gram-positive organisms, including some anaerobes. It is indicated for the treatment of
serious infections caused by sensitive strains of streptococci, pneumococci, and staphylococci. It generally
is reserved for patients who are allergic to penicillin because of the increased risk of pseudomembranous
colitis. It also serves as the starting material for the synthesis of clindamycin (by a SN-2
reaction that inverts the R stereochemistry of the C-7 hydroxyl to a C-7 S-chloride). | [Synthesis]
Lincomycin, 6,8-dideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidincarboxamido)-1-methylthio-D-erythro-α-D-galacto-octopyranoside (32.5.1), is the first
lincosamide that has found use in clinical practice, and which was isolated in 1962
from the culture liquid of the activity of the actinomycete Streptomyces lincolnensis. | [Veterinary Drugs and Treatments]
Lincomycin has dosage forms approved for use in dogs, cats, swine,
and in combination with other agents for chickens. Because clindamycin
is generally better absorbed, more active, and probably less
toxic, it has largely supplanted the use of lincomycin for oral and
injectable therapy in small animals, but some clinicians believe that
clindamycin does not offer enough clinically significant improvements
over lincomycin to justify its higher cost. For further information,
refer to the Pharmacology or Doses sections. | [storage]
Store at -20°C |
|
|